Trials / Completed
CompletedNCT06940466
A Cognitive Intervention to Manage 'Brain Fog' in Menopause Transition: Feasibility Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- University College, London · Academic / Other
- Sex
- Female
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Cognitive complaints at menopause transition (MT), often described as 'brain fog'; can include difficulty recalling words and numbers, misplacing items, trouble concentrating and forgetfulness. Whilst these difficulties resolve for most people, several years of reduced cognitive functioning can be highly damaging and result in problems including leaving work, depression and relationship breakdown. Study Aims: This project aims 1) to develop and finalise a cognitive intervention for the menopause, 2) To evaluate the feasibility, acceptability and preliminary effects of the intervention. 3) To evaluate the interventions preliminary effects on subjective and objective cognition Relevance: Traditionally Menopause Hormone Therapy (MHT) is offered to women with cognitive complaints due to its beneficial effect. However, many women are unable to take it due to medical reasons or choose not to. If this intervention is concluded as feasible and acceptable it may then be appropriate to conduct a full RCT of this intervention. It could reduce excess disability, potentially enabling people to remain at work and function better in daily life. Costs to the NHS might be reduced through decreased service and medication use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Online cognitive intervention | A 4 x 2-hour intervention with the following key components: education about menopause and cognition, cognitive strategies (memory, attention and executive functioning), CBT techniques and emotional support. |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2025-10-01
- Completion
- 2025-12-01
- First posted
- 2025-04-23
- Last updated
- 2026-02-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT06940466. Inclusion in this directory is not an endorsement.